Publicaciones en colaboración con investigadores/as de Ludwig Maximilian University of Munich (167)

2025

  1. Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses

    European Neuropsychopharmacology, Vol. 90, pp. 1-15

2024

  1. Costs and resource utilization patterns in surgical site infections: a pre-COVID-19 perspective from France, Germany, Spain, and the UK

    Journal of Hospital Infection, Vol. 147, pp. 123-132

  2. Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

    HemaSphere, Vol. 8, Núm. 7

  3. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

    Journal of Clinical Oncology, Vol. 42, Núm. 16, pp. 1875-1880

  4. Expert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma

    Journal of Glaucoma, Vol. 33, Núm. 10, pp. 715-727

  5. Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study

    Psychiatry Research, Vol. 342

  6. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

    Leukemia, Vol. 38, Núm. 8, pp. 1722-1730

  7. How gut microbiota may impact ocular surface homeostasis and related disorders

    Progress in Retinal and Eye Research, Vol. 100

  8. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Journal of Clinical Oncology, Vol. 42, Núm. 24, pp. 2918-2927

  9. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: Development and recalibration of the LIFE-CVD2 model to four European risk regions

    European Journal of Preventive Cardiology, Vol. 31, Núm. 14, pp. 1690-1699

  10. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217

  11. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

    Transplant Infectious Disease, Vol. 26, Núm. 1

  12. The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

    HemaSphere, Vol. 8, Núm. 6

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

    Molecular Psychiatry, Vol. 28, Núm. 3, pp. 1201-1209

  3. COVID19-associated new-onset movement disorders: a follow-up study

    Journal of Neurology, Vol. 270, Núm. 5, pp. 2409-2415

  4. Convergent activation of Ca2+ permeability in two-pore channel 2 through distinct molecular routes

    Science signaling, Vol. 16, Núm. 799, pp. eadg0661

  5. Dry eye disease sustainability

    Ocular Surface

  6. Management of inflammation in dry eye disease: Recommendations from a European panel of experts

    European Journal of Ophthalmology, Vol. 33, Núm. 3, pp. 1294-1307

  7. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4